Emergent BioSolutions to supply medical countermeasures to US
Category: #headlines  By Pankaj Singh  Date: 2019-03-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Emergent BioSolutions to supply medical countermeasures to US

The company would manufacture and deliver several medical countermeasures prescribed by the Department of State including auto-injector training devices, Reactive Skin Decontamination Lotion Kit, and the Trobigard auto-injector

Emergent BioSolutions Inc. has reportedly inked an IDIQ (indefinite-delivery, indefinite-quantity) agreement with the United States’ Department of State to establish a stable, reliable, and long-term supply chain for medical countermeasures to tackle chemical warfare agents.

According to a press release from Emergent BioSolutions, the agreement consists of a five-year base period of performance with five one-year option periods.

Senior Vice President and Head of the devices business unit of Emergent BioSolutions, Doug White was reportedly quoted saying that the company is delighted with the follow-on opportunity provided by the U.S. government to meet its medical countermeasures and improve the security of the nation’s diplomats and other Chief of Mission personnel involved in high-risk environments globally.

White further added that the company is looking forward to successfully deliver Trobigard auto-injector as part of the 2017 contract and to continue its collaboration with the State Department, while expanding the portfolio of solutions to address the upcoming chemical warfare agents in the long-term.

As part of the IDIQ agreement, Emergent BioSolutions would maintain the capacity to produce and deliver several medical countermeasures prescribed by the Department of State, including auto-injector training devices, Reactive Skin Decontamination Lotion Kit, and the Trobigard auto-injector.

Managing Director of operational medicine for the U.S. Department of State, William A. Walters, M.D. reportedly commented that one of the most significant responsibilities of the agency is to successfully respond to grave threats to diplomatic missions overseas and to ensure the safety of employees stationed there.

Ensuring adequate stockpiles of medical countermeasures and establishing a stable supply chain of the same is important as the department equips itself with the tools that enable an accurate, timely, and safe response to the highest risk chemical agents, Walters explained.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Merck acquires Calporta Therapeutics from COI Pharmaceuticals
Merck acquires Calporta Therapeutics from COI Pharmaceuticals
By Pankaj Singh

Merck will pay up to $576 million for the acquisition   Preclinical TRPML1 has the potential to treat neurodegenerative and lysosomal disorders COI Pharmaceuticals has recently announced that Merck, also called MSD outside Canada and the U...

Personalis unveils new service for cancer whole genome sequencing
Personalis unveils new service for cancer whole genome sequencing
By Pankaj Singh

  The new launch of the services will help the company expand its oncology portfolio Personalis has been able to sequence more than 40,000 MVP samples since 2013. Personalis, Inc., a leading advanced genomics firm for cancer, recently unve...

Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
By Pankaj Singh

Celltrion Healthcare, a biopharmaceutical company, recently announced data from a study further investigating efficacy, safety, immunogenicity & pharmacokinetics of CT-P13 SC, over a period of 1-year treatment. The study focuses on the results ac...